Shozo Mori
Overview
Explore the profile of Shozo Mori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
179
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miyashita S, Shimizu T, Niki M, Sato S, Tanaka G, Yamaguchi T, et al.
Anticancer Res
. 2025 Jan;
45(2):651-659.
PMID: 39890171
Background/aim: The incidence of hepatocellular carcinoma (HCC) associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatitis C virus sustained virologic response (HCV-SVR) are increasing. However, the mechanisms driving HCC...
2.
Funamizu N, Mori S, Sakamoto A, Iwata M, Shine M, Ito C, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39409992
Background: S-1 in adjuvant chemotherapy (AC) administration after pancreatic cancer (PC) surgery has been standardized in Japan. The Ehime study confirmed that a postoperative higher C-reactive protein-to-albumin ratio (CAR) value...
3.
Ishizuka M, Shibuya N, Hachiya H, Nishi Y, Kono T, Takayanagi M, et al.
Eur J Surg Oncol
. 2024 Jul;
50(10):108538.
PMID: 39053042
Objective: To investigate whether robotic surgery (RS) decreases the risk of circumferential resection margin (CRM) positivity compared with conventional laparoscopic surgery (LS) in patients with rectal cancer (RC) undergoing mesorectal...
4.
Matsumoto T, Shiraki T, Niki M, Sato S, Tanaka G, Shimizu T, et al.
Eur J Surg Oncol
. 2024 Apr;
50(6):108356.
PMID: 38685177
Background: Because repeat hepatectomy for recurrent hepatocellular carcinoma is a potentially invasive procedure, it is necessary to identify patients who truly benefit from repeat hepatectomy. Albumin-bilirubin grading has been reported...
5.
Ishizuka M, Shibuya N, Hachiya H, Nishi Y, Takayanagi M, Fujita J, et al.
J Gastrointest Surg
. 2024 Apr;
28(4):548-558.
PMID: 38583909
Background: Although several recent meta-analyses have investigated the clinical influence of the addition of lateral lymph node dissection (LLND) on oncologic outcomes in patients with mid-low rectal cancer (RC) undergoing...
6.
Aoki T, Mori S, Kubota K
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473272
In addition to established evidence of the efficacy of adjuvant chemotherapy (AC) for pancreatic ductal adenocarcinoma (PDAC), evidence of the effects of neoadjuvant treatments (NATs), including chemotherapy and chemoradiotherapy, has...
7.
Matsumoto T, Shiraki T, Tanaka G, Yamaguchi T, Park K, Mori S, et al.
World J Surg
. 2024 Mar;
48(5):1219-1230.
PMID: 38468392
Background: Despite the accumulating evidence regarding the oncological differences between nonalcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) and viral infection-related HCC, the short- and long-term outcomes of surgical resection...
8.
Matsumoto T, Tanaka G, Mori S, Niki M, Sato S, Shiraki T, et al.
Clin J Gastroenterol
. 2024 Feb;
17(3):537-542.
PMID: 38396137
A 72-year-old male patient presented to our department complaining of with upper abdominal pain and jaundice. He had a history of a side-to-side pancreaticojejunostomy performed 40 years previously for chronic...
9.
Suda K, Shimizu T, Ishizuka M, Miyashita S, Niki M, Shibuya N, et al.
Surg Endosc
. 2023 Dec;
38(2):1114.
PMID: 38117358
No abstract available.
10.
Sato S, Aoki T, Matsumoto T, Shiraki T, Mori S, Iso Y, et al.
Clin J Gastroenterol
. 2023 Dec;
17(2):292-299.
PMID: 38071671
The combination regimen of atezolizumab plus bevacizumab (Atezo/Bev) is currently used as first-line treatment in patients with unresectable hepatocellular carcinoma. Herein, we report a rare case of curative hepatic resection...